Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 18, 2016Human Vaccines & ImmunotherapeuticsOpen Access

The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model

View Full Paper
Ask AI
Bookmark
Share

Authors

HCHarrell W. ChessonCenters for Disease Control and PreventionLMLauri E. MarkowitzUniversity of VermontSHSusan HaririCenters for Disease Control and Prevention

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chesson et al. (2016) studied this question.

synapsesocial.com/papers/6a7e678afff18652e232fa74https://doi.org/10.1080/21645515.2016.1140288
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–20102013 · 524 citations
  2. 2Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States2009 · 231 citations
  3. 3Evidence of Human Papillomavirus Vaccine Effectiveness in Reducing Genital Warts: An Analysis of California Public Family Planning Administrative Claims Data, 2007–20102012 · 102 citations
  4. 4Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model2011 · 121 citations
  5. 5Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models2016 · 319 citations